Immunicum AB (publ) Interim Report January –

0

JANUARY MARCH IN SUMMARY

  • Net sales for the period amounted to KSEK 1,794 (–).
  • The result for the period amounted to KSEK -27,582 (-41,571).
  • Earnings and diluted earnings per share totaled -0.14 SEK (-0.25).
  • Immunicum Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics
  • Immunicum provided an overview of the pipeline and strategy. In 2022, clinical development will focus on i) continuation and further updates of clinical data from the ADVANCE II study evaluating DCP-001 for the maintenance treatment of acute myeloid leukemia (AML) ,
    ii) the continuation of the ALISON study in ovarian cancer, which will deliver a first clinical reading in 2022 and iii) the evaluation and preparation of the TROY study, which will evaluate the potential of Ilixadencel in tumors gastrointestinal stromal (GIST)
  • Immunicum has made further progress in establishing its new primary research facility in Leiden, the Netherlands, which will integrate the company’s process development and manufacturing capabilities for cell-based immune therapies. The company expects to finalize the move to its new facilities in the second quarter of 2022.
  • Continued progress in exploring potential synergies of Immunicum’s platform and product candidates with the current standard of care in Immunicum’s primary cancer indications, and other cell-based cancer therapies and biologics in development in oncology

COVID-19[feminine]UKRAINIAN CRISIS

  • To date, Immunicum has experienced only a limited impact on its operations due to the Covid-19 pandemic
  • Immunicum has no direct exposure to Ukraine and Russia due to day-to-day operations and ongoing clinical trials
  • Ongoing stock market and supply chain uncertainties could affect our longer-term operations
  • For more information, please refer to the section on risks on page 18.

SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD

  • Immunicum participates in the new cancer research consortium Oncode-PACT
  • Immunicum to Present Preclinical Data Demonstrating Synergy of DCP-001 with Standard Treatments for Acute Myeloid Leukemia
  • Immunicum Appoints Leopold Bertea as Chief Technology Officer

FINANCIAL SUMMARY

Jan-Mar Jan-Mar Full year
KSEK unless otherwise specified 2022 2021 2021
Operating profit/loss -26,820 -40,780 -130 100
Net profit/loss -27,582 -41,571 -133,410
Earnings/loss per share, before and after dilution (SEK) -0.14 -0.25 -0.73
Species 122,926 118,960 155,313
Equity 629 257 619 100 656 742
Number of employees at the end of the period 32 30 29

CEO COMMENT

“In the first quarter of 2022, Immunicum presented its revised pipeline and strategic outlook, via investor events held in Stockholm and Gothenburg, Sweden.

In 2022, we will have more visibility on how the promising initial effects of our DCP-001 cancer relapse vaccine presented at the ASH2021 conference last December will translate into potential relapse-free and overall survival benefit for patients. acute myeloid leukemia patients with measurable residual disease (MDR). We plan to provide an upcoming update of the ADVANCE II study based on full MRD data of all treated patients and relapse-free survival status in Q2 2022.

In the phase I ALISON study initiated in 2021, we are studying the safety and feasibility of DCP-001 in ovarian cancer. If successful, the trial could open the development of relapse vaccination as a new maintenance treatment for ovarian cancer. The first data from the ALISON study are expected in mid-2022.

Among the various indications studied so far with our intratumoral immune primer ilixadencel, we believe that gastrointestinal stromal tumors (GIST) represent the most attractive opportunity, due to the very low response rates to therapies currently available after initial treatment failure. Recently published results from the MERECA study in renal cell carcinoma have further enhanced our understanding of the biology and therapeutic combination potential of ilixadencel with tyrosine kinase inhibitors such as sunitinib. This provides an additional basis for our ongoing preparations in a clinical trial in combination with tyrosine kinase inhibitors in GISTs.

In the first quarter of 2022, we initiated the move to our new R&D facilities in Leiden, the Netherlands. Our in-house R&D expertise supports the clinical pipeline, the optimization of our manufacturing processes and partnership efforts. Immunicum participates in the new cancer research consortium Oncode-PACT, which is funded by the Dutch National Growth Fund and will support the expansion of our R&D facilities based in Leiden.

Despite the challenging conditions for the biopharmaceutical industry related to the Covid crisis, geopolitical instability and related hospital and supply chain disruption, the merger and integration of Immunicum and DCprime, directional decisions Pipeline improvements and exciting new R&D initiatives have enabled the company to make significant progress in 2021 and define our most promising programs in Q1 2022. We remain committed to addressing key challenges in the cancer therapy with competitive product candidates and look forward to further shaping our clinical pipeline in 2022.

Finally, as his appointment took place after the close of the reporting period, I would like to take this opportunity to welcome Leopold Bertea, PhD, as our new Chief Technology Officer. Leopold brings to Immunicum an impressive track record in cell therapy process development and production, including commercial scale manufacturing. He will lead the establishment of a global manufacturing infrastructure for DCP-001 and leverage the company’s process development capabilities for our current and future products.

Thanks,

Erik Manting, Ph.D.

Chief executive officer”

The Q1 2022 report is available at: http://immunicum.se/investors/financial-reports/

FOR MORE INFORMATION PLEASE CONTACT:

Erik Manting

Chief executive officer

Email: [email protected]

INVESTOR RELATIONS

Julie Seidel

Serious investor relations

Telephone: +1 212-362-1200

Email: [email protected]

MEDIA RELATIONS

Mario Brkulj

Valencia Communications

Telephone: +49 160 9352 9951

Email: [email protected]

ABOUT IMMUNICUM AB (PUBL)

Immunicum is a biopharmaceutical company specializing in therapies for tumor recurrence and hard-to-treat established tumors, two key challenges in oncology. We leverage our unrivaled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel off-the-shelf cell therapies for solid and blood-borne tumors. Based in Sweden and the Netherlands, Immunicum is listed on Nasdaq Stockholm. www.immunicum.com

  • 220510_Immunicum_Q1_2022_EN

  • Immunicum_Q1_2022_EN

Share.

Comments are closed.